Literature DB >> 25590159

Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis.

Philip A Reid1, David A McAllister, A Christopher Boyd, J Alastair Innes, David Porteous, Andrew P Greening, Robert D Gray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25590159      PMCID： PMC4347434          DOI： 10.1164/rccm.201407-1365LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  14 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

3.  Sputum and serum calprotectin are useful biomarkers during CF exacerbation.

Authors:  R D Gray; M Imrie; A C Boyd; D Porteous; J A Innes; A P Greening
Journal:  J Cyst Fibros       Date:  2010-03-17       Impact factor: 5.482

4.  Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.

Authors:  D Bilton; G Canny; S Conway; S Dumcius; L Hjelte; M Proesmans; B Tümmler; V Vavrova; K De Boeck
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

5.  Predictive 5-year survivorship model of cystic fibrosis.

Authors:  T G Liou; F R Adler; S C Fitzsimmons; B C Cahill; J R Hibbs; B C Marshall
Journal:  Am J Epidemiol       Date:  2001-02-15       Impact factor: 4.897

Review 6.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

7.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

8.  Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid.

Authors:  Gordon MacGregor; Robert D Gray; Thomas N Hilliard; Margaret Imrie; A Christopher Boyd; Eric W F W Alton; Andrew Bush; Jane C Davies; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  J Cyst Fibros       Date:  2008-02-01       Impact factor: 5.482

9.  Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Ruth H Keogh; Yanping Li; Judy L Jensen; William Walsh; Kristyn Packer; Teresa Clark; Holly Carveth; Jun Chen; Shaunessy L Rogers; Christen Lane; James Moore; Anne Sturrock; Robert Paine; David R Cox; John R Hoidal
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

10.  Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240
View more
  15 in total

1.  Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.

Authors:  Jonas C Schupp; Sara Khanal; Jose L Gomez; Maor Sauler; Taylor S Adams; Geoffrey L Chupp; Xiting Yan; Sergio Poli; Yujiao Zhao; Ruth R Montgomery; Ivan O Rosas; Charles S Dela Cruz; Emanuela M Bruscia; Marie E Egan; Naftali Kaminski; Clemente J Britto
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

2.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

Review 3.  Nutritional Immunity: S100 Proteins at the Host-Pathogen Interface.

Authors:  Joseph P Zackular; Walter J Chazin; Eric P Skaar
Journal:  J Biol Chem       Date:  2015-06-08       Impact factor: 5.157

Review 4.  Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.

Authors:  L Keith Scott; Robert Toner
Journal:  Lung       Date:  2017-06-16       Impact factor: 2.584

Review 5.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

6.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Authors:  Scott D Sagel; Valeria Thompson; James F Chmiel; Gregory S Montgomery; Samya Z Nasr; Elizabeth Perkett; Milene T Saavedra; Bonnie Slovis; Margaret M Anthony; Peggy Emmett; Sonya L Heltshe
Journal:  Ann Am Thorac Soc       Date:  2015-05

7.  Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.

Authors:  Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2022-04-16       Impact factor: 5.527

8.  Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Authors:  Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie
Journal:  Clin Transl Sci       Date:  2015-12-08       Impact factor: 4.689

Review 9.  Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases.

Authors:  Grigorios Chatziparasidis; Ahmad Kantar
Journal:  Children (Basel)       Date:  2021-05-21

10.  Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Authors:  Rahul Kalla; Nicholas A Kennedy; Nicholas T Ventham; Ray K Boyapati; Alex T Adams; Elaine R Nimmo; Micaela R Visconti; Hazel Drummond; Gwo-Tzer Ho; Rebecca J Pattenden; David C Wilson; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2016-09-06       Impact factor: 12.045
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.